- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.05. | UCB inks $2B Candid buyout to join Gilead in autoimmune field | ||
| 01.05. | 'M&A used to be the only way to go': Why Seaport Therapeutics' CEO opted for route to upsized $255M IPO | ||
| 01.05. | CBER chief Prasad steps aside, deputy takes the reins as search for successor continues | ||
| 01.05. | Ligand tries to disembark from part of Viking pact, alleging contract breach | ||
| 01.05. | J&J axes $5B CAR-T dream months after touting best-in-disease efficacy | ||
| 30.04. | AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal | ||
| 30.04. | Indivior warns of 'significant impact' on R&D team after opioid use disorder drug fails phase 2 | ||
| 30.04. | BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific | ||
| 30.04. | Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy | ||
| 30.04. | BeOne signs $2B deal for option on preclinical trispecific antibody from China's Huahui | ||
| 30.04. | GSK's $700M Alector bet blows up as Alzheimer's drug flunks phase 2 | ||
| 30.04. | Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs | ||
| 30.04. | AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M | ||
| 29.04. | FDA hits Newron's phase 3 schizophrenia trial with clinical hold in US after patient death | ||
| 29.04. | AstraZeneca restarts £300M investment in UK, but Merck not budging | ||
| 29.04. | Teva inks $700M Emalex buyout to bag near-approval Tourette drug | ||
| 29.04. | AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial | ||
| 29.04. | Which blockbuster is GSK gunning for next? CEO Miels is looking to oncology | ||
| 29.04. | GSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program | ||
| 28.04. | FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board | ||
| 28.04. | Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits | ||
| 28.04. | AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition | ||
| 28.04. | Incyte's JAK inhibitor scores phase 3 vitiligo wins but can't quite shake off Rinvoq | ||
| 28.04. | Erasca hits 'home run' with cancer data as analyst suggests stock drop prompted by patient death | ||
| 28.04. | Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.